Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals

Biochemical and Biophysical Research Communications

Volumn 405, Issue 2, 2011, Pages 285-290

  Hamanaka, Taichi ^a   Sakasegawa, Yuji ^a   Ohmoto, Akihiro ^a   Kimura, Tomohiro ^a   Ando, Takao ^b   Doh ura, Katsumi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUREHA CORPORATION   (Japan)

Author keywords

Immunotherapeutic agent; Prion; Prion infected cells; Protein bound polysaccharide K

Indexed keywords

KRESTIN; NEUTRALIZING ANTIBODY; PRION PROTEIN; PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOPHAGY; CELL FUNCTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STRUCTURE; SINGLE DRUG DOSE; SURVIVAL TIME;

ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; FUNGAL PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED STRAINS; POLYSACCHARIDES; PRION DISEASES; PRPC PROTEINS;

ANIMALIA; MUS;

EID: 79651470773     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.030     Document Type: Article

References (26)

1. Prusiner S.B. Molecular biology of prion diseases. Science 1991, 252:1515-1522.
2. Sim V.L., Caughey B. Recent advances in prion chemotherapeutics. Infect. Disord. Drug Targets 2009, 9:81-91.
3. Collinge J., Gorham M., Hudson F., Kennedy A., Keogh G., Pal S., Rossor M., Rudge P., Siddique D., Spyer M., Thomas D., Walker S., Webb T., Wroe S., Darbyshire J. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009, 8:334-344.
4. Tsuboi Y., Doh-Ura K., Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009, 29:632-636.
5. Kocisko D.A., Baron G.S., Rubenstein R., Chen J., Kuizon S., Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 2003, 77:10288-10294.
6. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA 2001, 98:9836-9841.
7. Kobayashi H., Matsunaga K., Fujii M. PSK as a chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 1993, 2:271-276.
8. Harada H., Sakagami H., Konno K., Sato T., Osawa N., Fujimaki M., Komatsu N. Antimicrobial activity induction by PSK subfractions: dependence on molecular weight. Infection 1989, 17:38-39.
9. Tsukagoshi S., Hashimoto Y., Fujii G., Kobayashi H., Nomoto K., Orita K. Krestin (PSK). Cancer Treat. Rev. 1984, 11:131-155.
10. Ohmura Y., Matsunaga K., Motokawa I., Sakurai K., Ando T. Protective effects of a protein-bound polysaccharide, PSK, on Candida albicans infection in mice via tumor necrosis factor-alpha induction. Int. Immunopharmacol. 2001, 1:1797-1811.
11. Kawasaki Y., Kawagoe K., Chen C.J., Teruya K., Sakasegawa Y., Doh-ura K. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J. Virol. 2007, 81:12889-12898.
12. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T., Iwaki T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 2004, 85:1785-1790.
13. Teruya K., Nishizawa K., Doh-ura K. Semisynthesis of a protein with cholesterol at the C-terminal, targeted to the cell membrane of live cells. Protein J. 2010, 29:493-500.
14. Fischer M., Rülicke T., Raeber A., Sailer A., Moser M., Oesch B., Brandner S., Aguzzi A., Weissmann C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996, 15:1255-1264.
15. Sarkar S., Rubinsztein D.C. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol. Biosyst. 2008, 4:895-901.
16. Aguib Y., Heiseke A., Gilch S., Riemer C., Baier M., Schätzl H.M., Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009, 5:361-369.
17. Naslavsky N., Stein R., Yanai A., Friedlander G., Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoforms. J. Biol. Chem. 1997, 272:6324-6331.
18. Caughey B., Raymond G.J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 1991, 266:18217-18223.
19. Vey M., Pilkuhn S., Wille H., Nixon R., DeArmond S.J., Smart E.J., Anderson R.G., Taraboulos A., Prusiner S.B. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl. Acad. Sci. USA 1996, 93:14945-14949.
20. Iwamaru Y., Shimizu Y., Imamura M., Murayama Y., Endo R., Tagawa Y., Ushiki-Kaku Y., Takenouchi T., Kitani H., Mohri S., Yokoyama T., Okada H. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation. J. Neurochem. 2008, 107:636-646.
21. Kim C.L., Karino A., Ishiguro N., Shinagawa M., Sato M., Horiuchi M. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 2004, 85:3473-3482.
22. Forloni G., Jussich S., Awan T., Colombo L., Angeretti N., Girola L., Bertani I., Poli G., Caramelli M., Grazia Bruzzone M., Farina L., Limido L., Rossi G., Giaccone G., Ironside J.W., Bugiani O., Salmona M., Tagliavini F. Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA 2002, 99:10849-10854.
23. Wasser S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl. Microbiol. Biotechnol. 2002, 60:258-274.
24. Ikuzawa M., Matsunaga K., Nishiyama S., Nakajima S., Kobayashi Y., Andoh T., Kobayashi A., Ohhara M., Ohmura Y., Wada T., Chikao Y. Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int. J. Immunopharmacol. 1988, 10:415-423.
25. Endoh H., Matsunaga K., Yoshikumi C., Kawai Y., Suzuki T., Nomoto K. Production of antiserum against antitumor protein-bound polysaccharide preparation, PSK (Krestin) and its pharmacological application. Int. J. Immunopharmacol. 1988, 10:103-109.
26. Sethi S., Lipford G., Wagner H., Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002, 360:229-230.